Balstilimab (BAL) + Topotecan + Vinorelbine + Gemcitabine + Irinotecan + Pemetrexed
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancer
Conditions
Advanced Cancer, Metastatic Cervical Cancer
Trial Timeline
Aug 2, 2021 → Oct 22, 2021
NCT ID
NCT04943627About Balstilimab (BAL) + Topotecan + Vinorelbine + Gemcitabine + Irinotecan + Pemetrexed
Balstilimab (BAL) + Topotecan + Vinorelbine + Gemcitabine + Irinotecan + Pemetrexed is a phase 3 stage product being developed by Agenus for Advanced Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04943627. Target conditions include Advanced Cancer, Metastatic Cervical Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04943627 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Advanced Cancer